3Hamajima N,Iwata H,Obata Y,et al.No association of the 5' promoter region polymorphism of CYP17 with breast cancer risk in Japan.Jpn J Cancer Res,2000,91 (9):880-885
4Haiman CA,Hankinson SE,Spiegelman D,et al.The relationship between a polvmorphism in CYP17 with plasma hormone levels and breast cances.Cancer Res,1999,59:1015-1020
5Feigelson HS,Shames LS,Pike MC,et al.Cytochrome P450c17α gene (CYP17) polymerphism is associated with serum estrogen and progesterone concentrations.Cancer Res,1998,58:585-587
6Brodie A,Long B,Lu Q.Aromatase expression in the human breast.Breast Cancer Res Treat,1998,49:S85-91
7Schmitt M,Klinga K,Schnarr B,et al.Dehydroepiandrosterone stimulates proliferation and gene expression in MCF-7 cells after conversion to estradiol.Mol Cell Endoerinol,2001,173(1-2):1-13
8Brueggemeier RW.Aromatase,aromatase inhibitors,and breast cancer.Am J Ther,2001,8(5):333-344
9Kristensen VN,Harada N,Kristensen T,et al.Genetic polymorphism and variability of steroid hormone metabolism:connection with risk of developing breast neoplasms.Vopr Onkol,2001,47(2):156-159
10Siegelmann-Danieli N,Buetow KH.Constitutional genetic variation at the human aromatase gene (Cyp 19) and breast cancer risk.Br J Cancer,1999,79(3-4):456-463
9Gorodeski GI. Estrogen modulation of epithelial permeability in cervical-vaginal cells of premenopausal and postmenopausal women[J]. Menopause,2007,14(6) :1012-1019.
10Delcominette S, Gaspard U. Female sexual dysfunction and postmenopausal androgen therapy [ J ]. Rev Med Liege, 2008,63 ( 1 ) :23-30.
